Patient-Reported Adverse Events with Adjunctive Tirzepatide or Semaglutide Treatment in Adults with Type 1 Diabetes - PubMed
2 days ago
- #Type 1 Diabetes
- #Semaglutide
- #Tirzepatide
- Adjunctive tirzepatide or semaglutide improves glucose control, reduces weight, and lowers insulin needs in overweight/obese adults with type 1 diabetes.
- Symptomatic hypoglycemia was more frequent with tirzepatide (29%) than semaglutide (13.4%).
- Gastrointestinal adverse events (AEs) were similar between tirzepatide and semaglutide groups.
- Young adults and females were more likely to report gastrointestinal AEs.
- Individualized risk assessment and close supervision are recommended when prescribing these off-label treatments.